Contact Us

Eminence Offers Global Commercial Licensing of CHO-K1 Host Cells to Facilitate Easy Application

Views: 0     Author: Site Editor     Publish Time: 2023-05-15      Origin: Site

facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

The CHO cells derived from Chinese hamster ovaries are the most widely used mammalian hosts in biological and medical research, especially for the expression of human therapeutic protein drugs. It's reported that approximately 70% of recombinant therapeutic protein drugs are produced using CHO cell systems.

The commonly used CHO cell lines include CHO-K1, CHO-DXB11, CHO-S, CHO-DG44 and CHO-GS, among which CHO-K1 cells are more frequently used in industrial production as they are transformed cell lines and hypodiploid cells. CHO-K1 cells are mainly derived from ATCC or ECACC, and the companies that have rights to commercial licensing are Lonza, Merck-Sigma, and Horizon. Due to their defined origin and safety assurance, CHO-K1 cell lines from these companies have been widely used in commercialized biopharmaceutical production, including monoclonal antibodies, polyclonal antibodies, recombinant proteins, vaccines, etc. However, pharmaceutical companies go through lengthy negotiation periods and pay high costs to obtain relevant licensing, including preliminary R&D licensing fees, investigational new drug application (IND) licensing fees, biologics license application (BLA) licensing fees, and subsequent profit sharing after product marketing.

To address the challenges faced by pharmaceutical companies, Eminence has introduced a CHO-K1 cell line (trade name: EM CHO-K1) from the source of CHO, for which it has full licensing right. It can be flexibly licensed to biopharmaceutical companies for project R&D and commercialized production or as a one-time non-exclusive buyout option. Currently, EM CHO-K1 cell lines have been used by customers in projects at the clinical study stage.

Eminence has established a complete EM CHO-K1 cell bank and carried out comprehensive testing via a third-party authoritative testing institution (Charles River Laboratories) according to GMP requirements, including identification, mycoplasma, sterility, adventitious pathogens, etc. (see Appendix 1)

Leveraging years of technical expertise, Eminence has developed expression vectors compatible with CHO cells for the expression of monoclonal antibodies, polyclonal antibodies and recombinant proteins. Depending on its extensive experience in the development of cell culture medium formulations, Eminence can also provide optimal development strategies to enhance cell line performance for clients.

Eminence performed comparative analyses of cell growth, doubling time, antibody expression titer and glycoform distribution between EM CHO-K1 cells and CHO-K1 cells obtained from the world's largest nonprofit biological resource center (In-house trade name: ACE CHO-K1). The results showed no significant differences between EM CHO-K1 and ACE CHO-K1 cells (see Figure I).


Figure 1: Cell Growth and Doubling Time

At the mini-pool stage, the antibody expression titer was also very similar, and there was no significant difference (see Figure II).


Figure 2: Mini-pool Antibody Expression Titer

The glycoform distribution showed that EM CHO-K1 had a lower Man5 content than ACE CHO-K1 (see Figure III).


Figure 3: Glycoform Distribution

Under the condition that there are no significant differences in cell growth, doubling time, antibody expression titer, and glycoform distribution, the EM CHO-K1 from Eminence provides domestic and international biopharmaceutical companies with an origin-defined, safe, reliable, and cost-effective choice of CHO-K1 host cells.

Appendix I Cell Line Testing Items


Supported Compliance



Terms of Use
©2022 Eminence Biotechnology (Suzhou) Co., Ltd. All Rights Reserved.